Bio-Rad Laboratories Inc (BIO)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | -2,342,500 | -850,104 | -4,704,270 | 5,438,150 | 4,907,640 |
| Revenue | US$ in thousands | 2,566,500 | 2,671,260 | 2,802,250 | 2,922,540 | 2,545,630 |
| Pretax margin | -91.27% | -31.82% | -167.87% | 186.08% | 192.79% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $-2,342,500K ÷ $2,566,500K
= -91.27%
The pretax margin for Bio-Rad Laboratories Inc has displayed significant fluctuations over the past five years.
In December 31, 2020, the pretax margin was exceptionally high at 192.79%, indicating that the company was able to generate a substantial profit before taxes relative to its revenue.
By December 31, 2021, the pretax margin slightly decreased to 186.08%, still reflecting a strong profitability level for the company.
However, a notable negative trend emerged in the subsequent years. By December 31, 2022, the pretax margin plummeted to -167.87%, indicating that the company incurred significant losses before taxes, potentially due to increased expenses or a decline in revenue.
The negative trend continued in December 31, 2023, with a pretax margin of -31.82%, suggesting ongoing financial challenges impacting the company's profitability.
By December 31, 2024, the pretax margin further declined to -91.27%, emphasizing the continued strain on Bio-Rad Laboratories Inc's financial performance.
Overall, the company experienced a sharp decline in pretax margin over the analyzed period, signaling potential financial difficulties that warrant further investigation and strategic measures to improve profitability.
Peer comparison
Dec 31, 2024